Preexisting Oral Anticoagulant Therapy Ameliorates Prognosis in Hospitalized COVID-19 Patients.
Front Cardiovasc Med
; 8: 633878, 2021.
Article
in English
| MEDLINE | ID: covidwho-1247846
ABSTRACT
Objective:
Altered coagulation parameters in COVID-19 patients is associated with a poor prognosis. We tested whether COVID-19 patients on chronic oral anticoagulants (cOACs) for thromboembolism prophylaxis could receive protection from developing more severe phenotypes of the disease. Approach andResults:
We searched the database of the SARS-RAS study (Clinicaltrials.gov NCT04331574), a cross-sectional observational multicenter nationwide survey in Italy designed by the Italian Society of Hypertension. The database counts 2,377 charts of Italian COVID-19 patients in 26 hospitals. We calculated the Charlson comorbidity index (CCI), which is associated with death in COVID-19 patients. In our population (n = 2,377, age 68.2 ± 0.4 years, CCI 3.04 ± 0.04), we confirm that CCI is associated with increased mortality [OR 1.756 (1.628-1.894)], admission to intensive care units [ICU; OR 1.074 (1.017-1.134)], and combined hard events [CHE; OR 1.277 (1.215-1.342)]. One hundred twenty-five patients were on cOACs (age 79.3 ± 0.9 years, CCI 4.35 ± 0.13); despite the higher CCI, cOACs patients presented with a lower risk of admissions to the ICU [OR 0.469 (0.250-0.880)] but not of death [OR 1.306 (0.78-2.188)] or CHE [OR 0.843 (0.541-1.312)]. In multivariable logistic regression, cOACs confirmed their protective effect on ICU admission and CHE. The CCI remains the most important risk factor for ICU admission, death, and CHE.Conclusions:
Our data support a mechanism for the continuation of cOAC therapy after hospital admission for those patients who are on chronic treatment. Our preliminary results suggest the prophylactic use of direct cOACs in patients with elevated CCI score at the time of the COVID-19 pandemic even in absence of other risks of thromboembolism.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Language:
English
Journal:
Front Cardiovasc Med
Year:
2021
Document Type:
Article
Affiliation country:
Fcvm.2021.633878
Similar
MEDLINE
...
LILACS
LIS